Dr. Mahdi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3990 John R 7 Brush North
Wayne State University Detroit Medical Centerobgyn
Detroit, MI 48201Phone+1 734-444-6406Fax+1 216-444-9423
Education & Training
Cleveland Clinic FoundationFellowship, Gynecologic Oncology, 2012 - 2015
University of WashingtonResidency, Obstetrics and Gynecology, 2009 - 2012
Wayne State University School of MedicineInternship, Transitional Year, 2008 - 2009
University of Al-Mustansiriyah College of MedicineClass of 2004
Certifications & Licensure
MI State Medical License 2008 - 2026
OH State Medical License 2012 - 2026
PA State Medical License 2020 - 2024- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Publications & Presentations
PubMed
- 1 citationsImmunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression.Paul G Pavicic Jr, Patricia A Rayman, Shadi Swaidani, Amit Rupani, Vladimir Makarov
Oncoimmunology. 2023-01-01 - 44 citationsThe Impact of Obesity on the 30-Day Morbidity and Mortality After Surgery for Endometrial CancerHaider Mahdi, A.M. Jernigan, Qataralnada Aljebori, David Lockhart, Mehdi Moslemi-Kebria
Journal of Minimally Invasive Gynecology. 2015-01-01 - 19 citationsDefining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery CommitteeBrian R. Gastman, Piyush K. Agarwal, Adam C. Berger, Genevieve M. Boland, Stephen Broderick
Journal for Immunotherapy of Cancer. 2020-11-01
Lectures
- The role of proinflammatory immune (IFN-gamma) gene signature in predicting prognosis and response to chemotherapy in uterine carcinoma.2019 ASCO Annual Meeting - 6/1/2019
- The role of different TGFβ signatures in predicting outcome in high grade serous ovarian carcinoma.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
ALX Oncology Doses First Patient in Trial of Evorpacept for Ovarian CancerMay 10th, 2023- ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian CancerMay 9th, 2023
- Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb's Immune Checkpoint Inhibitor OPDIVOFebruary 22nd, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
